Ex vivo Expanded Allogeneic Universal Donor NK Cells (TGFβi NK cells)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Ex vivo Expanded Allogeneic Universal Donor NK Cells (TGFβi NK cells), covering 2025-07-08 to 2025-07-08. Get the full timeline:
Most recent: Clinical Trial Update: Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer [Phase 1, Phase 2]